# Entecavir With or Without Pegylated Interferon α-2b in Children Aged 3-6 Years With Immune-Active Chronic Hepatitis B

> **NCT07345611** · PHASE4 · NOT_YET_RECRUITING · sponsor: **Qing-Lei Zeng** · enrollment: 60 (estimated)

## Conditions studied

- Hepatitis B Virus Infection
- Children
- Chronic Hepatitis B

## Interventions

- **DRUG:** Entecavir
- **DRUG:** Entecavir + Pegylated interferon α-2b

## Key facts

- **NCT ID:** NCT07345611
- **Lead sponsor:** Qing-Lei Zeng
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-01-11
- **Primary completion:** 2030-12-31
- **Final completion:** 2030-12-31
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-01-16

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07345611

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07345611, "Entecavir With or Without Pegylated Interferon α-2b in Children Aged 3-6 Years With Immune-Active Chronic Hepatitis B". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07345611. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*